Pulmonary hypertension in systemic lupus erythematosus: Pulmonary thromboembolism is the leading cause

Journal of Clinical Rheumatology

Volumn 19, Issue 8, 2013, Pages 421-425

  Akdogan, Ali ^a   Kilic, Levent ^a   Dogan, Ismail ^a   Okutucu, Sercan ^b   Er, Elif ^b   Kaya, Barş ^b   Coplu, Lutfi ^a   Calguneri, Meral ^a   Tokgozoglu, Lale ^b   Ertenli, Ihsan ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Department of Cardiology ^*  (Turkey)

Author keywords

Pulmonary hypertension; Pulmonary thromboembolism; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; BOSENTAN; CARDIOLIPIN ANTIBODY; HEMOGLOBIN; HYDROXYCHLOROQUINE; ILOPROST; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; SILDENAFIL; STEROID;

ADULT; ANEMIA; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE DURATION; DOPPLER ECHOCARDIOGRAPHY; ENDARTERECTOMY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART CATHETERIZATION; HEART OUTPUT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG ARTERY PRESSURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM;

ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; ULTRASONOGRAPHY, DOPPLER;

EID: 84889251375     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000037     Document Type: Article

References (33)

1. Smith PP, Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev. 2010;10:43-45.
2. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
3. Gomberg-Maitland M, Dufton C, Oudiz RJ, et al. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol. 2011;57:1053-1061.
4. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995;107:1193-1198.
5. Leung CC, Moondra V, Catherwood E, et al. Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction. Am J Cardiol. 2010;106:284-286.
6. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J. 2012;39:945-955.
7. Carreira PE. Pulmonary hypertension in autoimmune rheumatic diseases. Autoimmun Rev. 2004;3:313-320. (Pubitemid 38887627)
8. Quismorio FP Jr, Sharma O, Koss M, et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum. 1984;13:349-359. (Pubitemid 14079399)
9. Tan EM, Cohen AS, Fries JF, Masi AT, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277. (Pubitemid 13221242)
10. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:615-621.
11. Lang IM, Plank C, Sadushi-Kolici R, et al. Imaging in pulmonary hypertension. JACC Cardiovasc Imaging. 2010;3:1287-1295.
12. Scalzi LV, Hollenbeak CS, Wang L. Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus. Arthritis Rheum. 2010;62:2767-2775.
13. Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol. 2009;23:469-480.
14. Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosusVa meta-analysis. Lupus. 1997;6:467-473. (Pubitemid 27395386)
15. O'Callaghan DS, Dorfmuller P, Jais X, et al. Pulmonary veno-occlusive disease: the bete noire of pulmonary hypertension in connective tissue diseases? Presse Med. 2011;40(1 pt 2):e65-e78.
16. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011-2020.
17. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:325-331.
18. Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev. 2006;5:344-348. (Pubitemid 43868201)
19. Fedullo PF, Rubin LJ, Kerr KM, et al. The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J. 2000;15:435-437. (Pubitemid 30158176)
20. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29:298-310.
21. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792-3800. (Pubitemid 41798217)
22. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev. 2010;9:A311-A318.
23. Shirai Y, Yasuoka H, Okano Y, et al. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. Rheumatology (Oxford). 2012;51:1846-1854.
24. Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68:620-628.
25. Greyson CR. The right ventricle and pulmonary circulation: basic concepts. Rev Esp Cardiol. 2010;63:81-95.
26. Havlucu Y, Kursat S, Ekmekci C, et al. Pulmonary hypertension in patients with chronic renal failure. Respiration. 2007;74:503-510. (Pubitemid 47206879)
27. Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918-3925. (Pubitemid 44955895)
28. Cefle A, Inanc M, Sayarlioglu M, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int. 2011;31:183-189.
29. Gibbs JS. Treating pulmonary arterial hypertension: is it worth it? Heart. 2010;96:1607-1608.
30. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004;43:461-466. (Pubitemid 38489363)
31. Urbanus RT, de Groot PG. Antiphospholipid antibodiesVwe are not quite there yet. Blood Rev. 2011;25:97-106.
32. Lian F, Chen D, Wang Y, et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int. 2012;32:1727-1731.
33. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521-531. (Pubitemid 351294886)